Biogen Inc. (0R1B.L)
USD 150.06
(-0.94%)
USD 150.06
(-0.94%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 7.18 Billion USD | 8.68% |
| 2022 | 6.61 Billion USD | 0.15% |
| 2021 | 6.6 Billion USD | -15.63% |
| 2020 | 7.82 Billion USD | 60.69% |
| 2019 | 4.87 Billion USD | -17.94% |
| 2018 | 5.93 Billion USD | 0.03% |
| 2017 | 5.93 Billion USD | -8.87% |
| 2016 | 6.51 Billion USD | -0.13% |
| 2015 | 6.52 Billion USD | 1020.42% |
| 2014 | 582.06 Million USD | -1.75% |
| 2013 | 592.43 Million USD | -13.81% |
| 2012 | 687.39 Million USD | -35.2% |
| 2011 | 1.06 Billion USD | -0.52% |
| 2010 | 1.06 Billion USD | -1.28% |
| 2009 | 1.08 Billion USD | -0.48% |
| 2008 | 1.08 Billion USD | 1993.69% |
| 2007 | 51.84 Million USD | -46.38% |
| 2006 | 96.69 Million USD | 122.57% |
| 2005 | 43.44 Million USD | -57.36% |
| 2004 | 101.87 Million USD | -88.52% |
| 2003 | 887.27 Million USD | 2271.75% |
| 2002 | 37.41 Million USD | -51.59% |
| 2001 | 77.27 Million USD | -26.01% |
| 2000 | 104.43 Million USD | -3.46% |
| 1999 | 108.17 Million USD | 89.91% |
| 1998 | 56.96 Million USD | -7.9% |
| 1997 | 61.84 Million USD | -0.66% |
| 1996 | 62.25 Million USD | 89.65% |
| 1995 | 32.82 Million USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| 1990 | - USD | 0.0% |
| 1989 | - USD | -100.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 6.29 Billion USD | -7.34% |
| 2024 Q2 | 6.29 Billion USD | 0.03% |
| 2024 Q3 | 4.9 Billion USD | -27.75% |
| 2023 Q3 | 7.21 Billion USD | 9.5% |
| 2023 Q2 | 6.58 Billion USD | -0.31% |
| 2023 FY | 7.18 Billion USD | 8.68% |
| 2023 Q1 | 6.6 Billion USD | -0.07% |
| 2023 Q4 | 7.18 Billion USD | -0.37% |
| 2022 Q1 | 6.58 Billion USD | -0.25% |
| 2022 FY | 6.61 Billion USD | 0.15% |
| 2022 Q4 | 6.61 Billion USD | -0.3% |
| 2022 Q3 | 6.63 Billion USD | 1.26% |
| 2022 Q2 | 6.55 Billion USD | -0.55% |
| 2021 FY | 6.6 Billion USD | -15.63% |
| 2021 Q1 | 7.64 Billion USD | -2.31% |
| 2021 Q4 | 6.6 Billion USD | -0.24% |
| 2021 Q3 | 6.62 Billion USD | -13.27% |
| 2021 Q2 | 7.63 Billion USD | -0.18% |
| 2020 Q2 | 7.83 Billion USD | 61.17% |
| 2020 Q4 | 7.82 Billion USD | -0.08% |
| 2020 Q3 | 7.83 Billion USD | -0.06% |
| 2020 FY | 7.82 Billion USD | 60.69% |
| 2020 Q1 | 4.86 Billion USD | -0.17% |
| 2019 Q4 | 4.87 Billion USD | 0.06% |
| 2019 Q3 | 4.86 Billion USD | -23.59% |
| 2019 Q1 | 6.37 Billion USD | 7.46% |
| 2019 Q2 | 6.37 Billion USD | -0.12% |
| 2019 FY | 4.87 Billion USD | -17.94% |
| 2018 FY | 5.93 Billion USD | 0.03% |
| 2018 Q2 | 5.92 Billion USD | -0.02% |
| 2018 Q3 | 5.93 Billion USD | 0.05% |
| 2018 Q4 | 5.93 Billion USD | 0.09% |
| 2018 Q1 | 5.92 Billion USD | -0.09% |
| 2017 Q4 | 5.93 Billion USD | -0.06% |
| 2017 Q2 | 5.95 Billion USD | 0.02% |
| 2017 Q1 | 5.95 Billion USD | -8.6% |
| 2017 FY | 5.93 Billion USD | -8.87% |
| 2017 Q3 | 5.93 Billion USD | -0.26% |
| 2016 Q1 | 6.53 Billion USD | 0.22% |
| 2016 Q2 | 6.53 Billion USD | 0.04% |
| 2016 Q3 | 6.52 Billion USD | -0.13% |
| 2016 FY | 6.51 Billion USD | -0.13% |
| 2016 Q4 | 6.51 Billion USD | -0.26% |
| 2015 Q2 | 576.2 Million USD | -0.77% |
| 2015 Q3 | 6.52 Billion USD | 1033.15% |
| 2015 Q1 | 580.67 Million USD | -0.24% |
| 2015 Q4 | 6.52 Billion USD | -0.12% |
| 2015 FY | 6.52 Billion USD | 1020.42% |
| 2014 Q2 | 586.09 Million USD | -0.83% |
| 2014 Q3 | 583.97 Million USD | -0.36% |
| 2014 Q1 | 591.01 Million USD | -0.24% |
| 2014 FY | 582.06 Million USD | -1.75% |
| 2014 Q4 | 582.06 Million USD | -0.33% |
| 2013 Q3 | 694.89 Million USD | -4.34% |
| 2013 FY | 592.43 Million USD | -13.81% |
| 2013 Q4 | 592.43 Million USD | -14.74% |
| 2013 Q2 | 726.38 Million USD | 2.05% |
| 2013 Q1 | 711.83 Million USD | 3.55% |
| 2012 Q4 | 687.39 Million USD | 4.4% |
| 2012 FY | 687.39 Million USD | -35.2% |
| 2012 Q1 | 626.01 Million USD | -40.99% |
| 2012 Q2 | 641.56 Million USD | 2.48% |
| 2012 Q3 | 658.44 Million USD | 2.63% |
| 2011 Q1 | 1.06 Billion USD | -0.07% |
| 2011 Q3 | 1.06 Billion USD | -0.22% |
| 2011 FY | 1.06 Billion USD | -0.52% |
| 2011 Q4 | 1.06 Billion USD | 0.02% |
| 2011 Q2 | 1.06 Billion USD | -0.25% |
| 2010 Q1 | 1.07 Billion USD | -0.37% |
| 2010 FY | 1.06 Billion USD | -1.28% |
| 2010 Q4 | 1.06 Billion USD | -0.22% |
| 2010 Q3 | 1.06 Billion USD | -0.09% |
| 2010 Q2 | 1.06 Billion USD | -0.6% |
| 2009 Q3 | 1.08 Billion USD | 0.02% |
| 2009 Q4 | 1.08 Billion USD | -0.52% |
| 2009 FY | 1.08 Billion USD | -0.48% |
| 2009 Q1 | 1.08 Billion USD | -0.23% |
| 2009 Q2 | 1.08 Billion USD | 0.25% |
| 2008 Q1 | 1.06 Billion USD | 1945.5% |
| 2008 Q4 | 1.08 Billion USD | 4.13% |
| 2008 Q3 | 1.04 Billion USD | 0.42% |
| 2008 FY | 1.08 Billion USD | 1993.69% |
| 2008 Q2 | 1.03 Billion USD | -2.11% |
| 2007 FY | 51.84 Million USD | -46.38% |
| 2007 Q1 | 52.04 Million USD | -46.18% |
| 2007 Q2 | 51.34 Million USD | -1.34% |
| 2007 Q3 | 50.11 Million USD | -2.41% |
| 2007 Q4 | 51.84 Million USD | 3.45% |
| 2006 Q1 | 43.97 Million USD | 1.23% |
| 2006 Q2 | 44.52 Million USD | 1.25% |
| 2006 Q3 | 45.07 Million USD | 1.23% |
| 2006 FY | 96.69 Million USD | 122.57% |
| 2006 Q4 | 96.69 Million USD | 114.52% |
| 2005 Q4 | 43.44 Million USD | 1.21% |
| 2005 Q1 | 94.75 Million USD | -6.99% |
| 2005 Q2 | 42.4 Million USD | -55.25% |
| 2005 Q3 | 42.92 Million USD | 1.23% |
| 2005 FY | 43.44 Million USD | -57.36% |
| 2004 FY | 101.87 Million USD | -88.52% |
| 2004 Q3 | 845.7 Million USD | -2.37% |
| 2004 Q1 | 861.29 Million USD | -2.93% |
| 2004 Q2 | 866.22 Million USD | 0.57% |
| 2004 Q4 | 101.87 Million USD | -87.95% |
| 2003 Q3 | 34.16 Million USD | -2.3% |
| 2003 Q2 | 34.96 Million USD | -33.43% |
| 2003 FY | 887.27 Million USD | 2271.75% |
| 2003 Q4 | 887.27 Million USD | 2497.32% |
| 2003 Q1 | 52.52 Million USD | 40.41% |
| 2002 FY | 37.41 Million USD | -51.59% |
| 2002 Q3 | 67.85 Million USD | -5.8% |
| 2002 Q2 | 72.03 Million USD | -1.82% |
| 2002 Q1 | 73.36 Million USD | -5.05% |
| 2002 Q4 | 37.41 Million USD | -44.87% |
| 2001 Q3 | 97.16 Million USD | -1.02% |
| 2001 Q2 | 98.17 Million USD | -0.88% |
| 2001 Q1 | 99.03 Million USD | -5.17% |
| 2001 FY | 77.27 Million USD | -26.01% |
| 2001 Q4 | 77.27 Million USD | -20.47% |
| 2000 Q4 | 104.43 Million USD | 113.9% |
| 2000 FY | 104.43 Million USD | -3.46% |
| 2000 Q1 | 51.26 Million USD | -52.61% |
| 2000 Q3 | 48.82 Million USD | -1.62% |
| 2000 Q2 | 49.63 Million USD | -3.19% |
| 1999 FY | 108.17 Million USD | 89.91% |
| 1999 Q3 | 53.7 Million USD | -1.47% |
| 1999 Q4 | 108.17 Million USD | 101.44% |
| 1999 Q2 | 54.5 Million USD | -3.02% |
| 1999 Q1 | 56.2 Million USD | -1.33% |
| 1998 Q1 | 61 Million USD | -1.37% |
| 1998 Q4 | 56.96 Million USD | -2.8% |
| 1998 Q3 | 58.6 Million USD | -1.35% |
| 1998 Q2 | 59.4 Million USD | -2.62% |
| 1998 FY | 56.96 Million USD | -7.9% |
| 1997 Q3 | 63.5 Million USD | -1.24% |
| 1997 Q1 | 66 Million USD | 6.02% |
| 1997 Q2 | 64.3 Million USD | -2.58% |
| 1997 Q4 | 61.84 Million USD | -2.6% |
| 1997 FY | 61.84 Million USD | -0.66% |
| 1996 Q4 | 62.25 Million USD | 3.76% |
| 1996 Q1 | 39.9 Million USD | 21.55% |
| 1996 Q2 | 51 Million USD | 27.82% |
| 1996 Q3 | 60 Million USD | 17.65% |
| 1996 FY | 62.25 Million USD | 89.65% |
| 1995 Q4 | 32.82 Million USD | 12.8% |
| 1995 Q3 | 29.1 Million USD | 24.89% |
| 1995 Q2 | 23.3 Million USD | -3.72% |
| 1995 FY | 32.82 Million USD | 0.0% |
| 1995 Q1 | 24.2 Million USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| 1991 Q2 | - USD | 0.0% |
| 1991 Q4 | - USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1989 Q4 | - USD | 0.0% |
| 1989 Q3 | - USD | 0.0% |
| 1989 FY | - USD | -100.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -29393.681% |
| Dynavax Technologies Corporation | 252.41 Million USD | -2747.737% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -21553.814% |
| Perrigo Company plc | 3.63 Billion USD | -97.869% |
| Illumina, Inc. | 1.48 Billion USD | -382.754% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 77.04% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -718720.0% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 10.639% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 44.514% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -4037.022% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -165.944% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -30437.406% |
| Waters Corporation | 2.3 Billion USD | -211.783% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -21347.71% |
| Evolus, Inc. | 120.35 Million USD | -5872.3% |
| Adicet Bio, Inc. | 17.7 Million USD | -40504.417% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -19286.175% |
| bluebird bio, Inc. | 224.41 Million USD | -3103.026% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -1333.209% |
| FibroGen, Inc. | 89.69 Million USD | -7913.869% |
| Agilent Technologies, Inc. | 2.73 Billion USD | -162.823% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -221851.806% |
| Homology Medicines, Inc. | 43.17 Million USD | -16548.601% |
| Geron Corporation | 35.05 Million USD | -20407.831% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | -206.792% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -1753.307% |
| Myriad Genetics, Inc. | 130.9 Million USD | -5391.367% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -767870.085% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -7329.894% |
| Zoetis Inc. | 6.56 Billion USD | -9.509% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -163193.957% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | -263.858% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -1111.981% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -891.886% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -20924.276% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -413.305% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -15631.512% |
| Verastem, Inc. | 40.08 Million USD | -17831.946% |
| Nektar Therapeutics | 112.62 Million USD | -6282.42% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -3936.727% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -233738.647% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -534.711% |
| OPKO Health, Inc. | 222.03 Million USD | -3137.432% |
| Exelixis, Inc. | 189.94 Million USD | -3684.379% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -2682.888% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | -5426.621% |
| Imunon, Inc. | 1.13 Million USD | -630835.15% |
| Blueprint Medicines Corporation | 610.96 Million USD | -1076.538% |
| Insmed Incorporated | 1.19 Billion USD | -502.354% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -379.454% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -12513.533% |
| TG Therapeutics, Inc. | 100.11 Million USD | -7079.728% |
| Incyte Corporation | 29.16 Million USD | -24549.201% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -1509.899% |